Acceleron Pharma Inc Quick Ratio (XLRN) starting from the third quarter 2021 to third quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Acceleron Pharma inc  (NASDAQ: XLRN)

Acceleron Pharma Inc's Quick Ratio

XLRN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2021, Quick Ratio deteriorated to 10.29 below Acceleron Pharma Inc's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 72 other companies have achieved higher Quick Ratio than Acceleron Pharma Inc in third quarter 2021. While Quick Ratio total ranking in the third quarter 2021 has deteriorated compared to the prior quarter from 650 to 732.

Explain Quick Ratio?
How much Cash & cash equivalents XLRN´s has?
What are XLRN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XLRN Quick Ratio (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3
Y / Y Current Liabilities Change 53.8 % 59.2 % 74.62 % 80.27 % 17.9 %
Y / Y Cash & cash equivalent Change -33.07 % 59.91 % 65.83 % 97.02 % 107.09 %
Quick Ratio MRQ 10.29 10.48 13.79 14.13 23.65
XLRN's Total Ranking # 732 # 650 # 495 # 484 # 156
Seq. Current Liabilities Change -3.54 % 19.39 % -17.19 % 61.29 % -0.16 %
Seq. Cash & cash equivalent Change -5.26 % -9.3 % -19.14 % -3.68 % 126.36 %



Quick Ratio third quarter 2021 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 73
Healthcare Sector # 351
Overall Market # 732


Quick Ratio Statistics
High Average Low
23.65 13.34 1.04
(Sep 30 2020)   (Dec 31 2012)




Financial Statements
Acceleron Pharma Inc's Current Liabilities $ 57 Millions Visit XLRN's Balance sheet
Acceleron Pharma Inc's Cash & cash equivalent $ 591 Millions Visit XLRN's Balance sheet
Source of XLRN's Sales Visit XLRN's Sales by Geography


Cumulative Acceleron Pharma Inc's Quick Ratio

XLRN's Quick Ratio for the trailling 12 Months

XLRN Quick Ratio

 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months
Y / Y Current Liabilities TTM Growth 66.1 % 57.95 % 54.39 % 42.87 % 36.73 %
Y / Y Cash & cash equivalent TTM Growth 29.89 % 83.12 % 65 % 46.98 % 33.56 %
Quick Ratio TTM 12.13 14.72 15.21 15.53 15.51
Total Ranking TTM # 4301 # 3923 # 172 # 64 # 121
Seq. Current Liabilities TTM Growth 9.71 % 11.98 % 13.03 % 19.62 % 4.33 %
Seq. Cash & cash equivalent TTM Growth -9.59 % 8.31 % 10.76 % 19.76 % 27.46 %

Quick ratio ranking by company, industry and sector >> Back to XLRN Financial Strength Comparisons >> Go to Compare XLRN Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2021 to $57.37 millions, cumulative Quick Ratio decreased to 12.13 below the Acceleron Pharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 145 other companies have achieved higher Quick Ratio than Acceleron Pharma Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2021 from 3923 to 4301.

Explain Quick Ratio?
How much Cash & cash equivalents XLRN´s has?
What are XLRN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 146
Healthcare Sector # 960
Within the Market # 4301


trailing twelve months Quick Ratio Statistics
High Average Low
19.88 13.85 8.87
(Jun 30 2018)   (Mar 31 2017)




Companies with similar Quick Ratio in the quarter ending Sep 30 2021, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2021 MRQ Cash & cash equivalentSep 30 2021 MRQ Current Liabilities
Vor Biopharma Inc   28.03 $ 225.968  Millions$ 8.063  Millions
In8bio Inc   26.55 $ 40.675  Millions$ 1.532  Millions
Replimune Group Inc   26.19 $ 435.771  Millions$ 16.636  Millions
Crispr Therapeutics Ag  25.75 $ 2,477.360  Millions$ 96.206  Millions
Leonabio Inc   25.12 $ 235.775  Millions$ 9.386  Millions
Renovacor Inc   23.15 $ 85.321  Millions$ 3.686  Millions
Kymera Therapeutics Inc   21.78 $ 536.386  Millions$ 24.627  Millions
Tenaya Therapeutics Inc   20.48 $ 280.465  Millions$ 13.692  Millions
Vivosim Labs Inc   20.17 $ 33.791  Millions$ 1.675  Millions
Candel Therapeutics Inc   20.10 $ 88.385  Millions$ 4.397  Millions
Atyr Pharma Inc   19.99 $ 116.354  Millions$ 5.820  Millions
Immunovant Inc   19.69 $ 558.952  Millions$ 28.383  Millions
Ginkgo Bioworks Holdings Inc   19.26 $ 1,739.056  Millions$ 90.305  Millions
Denali Therapeutics Inc   19.15 $ 1,039.175  Millions$ 54.251  Millions
Solid Biosciences Inc   18.80 $ 229.760  Millions$ 12.224  Millions
Biocardia Inc   18.78 $ 15.888  Millions$ 0.846  Millions
Achilles Therapeutics Plc  18.21 $ 266.319  Millions$ 14.628  Millions
Tcr2 Therapeutics Inc   17.90 $ 295.741  Millions$ 16.520  Millions
Freeline Therapeutics Holdings Plc  17.89 $ 136.377  Millions$ 7.621  Millions
Tarsus Pharmaceuticals Inc   17.73 $ 183.801  Millions$ 10.365  Millions
Ocugen Inc   17.72 $ 107.349  Millions$ 6.057  Millions
Inmune Bio Inc   17.56 $ 84.471  Millions$ 4.810  Millions
Elevation Oncology inc   17.48 $ 155.198  Millions$ 8.880  Millions
Miromatrix Medical inc   17.45 $ 62.088  Millions$ 3.558  Millions
Finch Therapeutics Group Inc   16.86 $ 149.200  Millions$ 8.851  Millions
Caribou Biosciences Inc   16.64 $ 435.310  Millions$ 26.158  Millions
Bluebird Bio Inc   16.57 $ 1,941.430  Millions$ 117.173  Millions
Inhibikase Therapeutics Inc   16.56 $ 44.846  Millions$ 2.708  Millions
Omega Therapeutics Inc   16.37 $ 234.275  Millions$ 14.309  Millions
Fusion Pharmaceuticals Inc   15.74 $ 192.617  Millions$ 12.236  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.